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ABSTRACT
Streptococcus agalactiae is a major bacterial streptococcosis disease that infects tilapia. This study aimed to 
analyze a specific and nonspecific immune system in fry tilapia that has been given with S. agalactiae vaccine 
from N3M and N4M strain and examine the protective immunity against S. agalactiae N3M, N4M, N17O, NK1,  and 
N14G strains infection. Fry tilapia used in this study has the weight of 7.086±0.948 g and length of 7.443±0.353 
cm. The S. agalactiae strains that used were N3M, N4M, N17O, NK1, and N14G. Fry tilapia was vaccinated through 
intraperitoneal injection method with 0.1 mL per fish of N3M and N4M vaccines. Fish reared in aquarium sizing 
of 60×30×50 cm3 with a density of 10 fishes/aquarium. Two weeks after vaccination, fry tilapia was tested with 
0.1 mL/fish of each N3M, N4M, N17O, NK1, and N14G strains through intraperitoneal injection method. Antibody 
level measured with indirect enzym-linked immunosorbent assay (ELISA) method. The result of antibody level in 
vaccinated fish after vaccination of N3M, N4M vaccine, N3M and N4M control were 0.767; 0.743; 0.587; and 0.544, 
respectively. Relative percent survival in N3M vaccinated fish after challenged with N3M and N4M was 87.50% 
dan 64.70%, respectively, otherwise in N4M vaccinated fish was 62.50% dan 76.47%, respectively. N3M and N4M 
vaccine strain have better protection as only if it tested with similar bacteria strain.
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ABSTRAK
Streptococcus agalactiae merupakan bakteri utama penyakit streptococcosis yang menginfeksi ikan nila. Tujuan 
penelitian ini adalah menganalisis sistem imun spesifik dan nonspesifik pada benih ikan nila yang diberi vaksin 
S. agalactiae strain N3M dan N4M serta mengkaji imunitas protektif terhadap infeksi S. agalactiae strain N3M, 
N4M, N17O, NK1, dan N14G. Benih ikan nila yang digunakan memiliki bobot 7,086 ± 0,948 g dan panjang 7,443 
± 0,353 cm. Bakteri yang digunakan adalah S. agalactiae strain N3M, N4M, N17O, NK1, dan N14G. Benih ikan 
nila divaksinasi menggunakan metode injeksi pada bagian intraperitoneal sebanyak 0,1 mL/ekor vaksin N3M dan 
N4M. Pemeliharaan dilakukan pada akuarium berukuran 60×30×50 cm3 dengan kepadatan 10 ekor/akuarium. 
Dua minggu setelah vaksinasi benih ikan diuji tantang dengan strain bakteri N3M, N4M, N17O, NK1,  dan N14G 
menggunakan metode injeksi pada bagian intraperitoneal dengan dosis 0,1 mL/ekor. Level antibodi diukur dengan 
metode indirect enzym-linked immunosorbent assay (ELISA). Hasil menunjukkan level antibodi ikan setelah 
vaksinasi pada perlakuan vaksin N3M, N4M, kontrol N3M, dan kontrol N4M berturut-turut 0,767; 0,743; 0,587; 
dan 0,544. Kelangsungan hidup relatif ikan yang divaksin N3M setelah diuji tantang dengan strain N3M dan N4M 
berturut-turut 87,50% dan 64,70%, sedangkan pada ikan yang divaksin N4M berturut-turut 62,50% dan 76,47%. 
Vaksin strain N3M dan N4M memiliki proteksi lebih baik jika diuji tantang dengan strain bakteri yang sama.
Kata kunci: formalin-killed cell, Streptococcus agalactiae, strain, proteksi, nila
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INTRODUCTION
Development of intensive tilapia fish farming 
caused disease problems, such as the viral, 
bacterial, and parasitic disease which needed to 
get more attention. Disease outbreak in fish was 
caused by a low fish defense, endurance, feed 
quality, and water quality (Giordano et al., 2010). 
One of the bacterial diseases which often attacked 
tilapia was streptococcosis (Sheehan et al., 2009). 
Streptococcosis was a disease caused by bacterial 
pathogen Streptococcus sp. (Abuseliana et al., 
2011). Indonesia became one of the countries 
exposed mass mortality on tilapia farming as the 
result of streptococcosis outbreaks (Taukhid & 
Purwaningsih, 2011). Tilapia intensive culture 
had a high risk of great loss as streptococcosis 
disease caused more than 90% mortality from the 
population (Ye et al., 2012).
Tilapia fish which was infected by 
Streptococcus agalactiae suffered exophthalmia, 
opacity, purulent, whirling, discoloration, 
abdominal abscess, and clear operculum (Hardi 
et al., 2011). Isolation of S. agalactiae from some 
regions in Indonesia which were discovered from 
streptococcosis disease outbreak obtained some 
isolation strains, such as N3M (eyes), N4M (eyes), 
N17O (brain), N14G (kidney) came from Cirata 
and NK1 (brain) came from Klaten (Hardi et al., 
2013).  S. agalactiae was the main bacteria which 
attacked various freshwater, brackishwater, and 
marine fish in the tropical and subtropical region, 
infecting fry until adult stadia (Bowater et al., 
2012).          
Some steps that have been made to control 
this disease outbreak were the use of antibiotics 
and other chemical products. However, these 
treatments had an impact on the environment and 
human health in a long period (Giordano et al., 
2010). One way to prevent a disease outbreak 
is vaccination (Chen et al., 2012). This activity 
would help form specific and non-specific 
immune system. Vaccination also formed a long-
term memory for the immune system, therefore 
it only took one or two times for the treatment of 
fish (Barman et al., 2013).
Vaccination on tilapia fish had been tested to be 
capable to enhance specific antibody formation and 
to protect from S. agalactiae infection (Giordano 
et al., 2010; Chen et al., 2012; Hardi et al., 2013). 
However, S. agalactiae from the isolation result 
contains too many strains, producing various 
type of vaccine. Every vaccine from S. agalactiae 
strain has a different protection mechanism. Hardi 
et al. (2013) reported that fish which was given S. 
agalactiae N14G strain after challenged with N14G 
and NK1 strain produced relative percent survival 
as much as 79% and 75% respectively, while fish 
vaccinated with NK1 strain, then challenged with 
N14G and NK1 strain produced relative percent 
survival as much as 62.5% and 75%, respectively. 
Fish that had been vaccinated by the different 
strain of S. agalactiae showed crossed protection 
in the sampled tilapia (Sukenda et al., 2014). 
Various vaccine type made the vaccine was 
difficult to choose for protecting the fish from 
S. agalactiae exposed strain. Information about 
the effectivity of a vaccine for protecting the fish 
from S. agalactiae strain infections is necessary 
to be discovered. This study aimed to analyze 
the specific and nonspecific immune system on 
the tilapia fry which was given S. agalactiae 
strain N3M and N4M, as well as investigating the 
protective immunity against S. agalactiae N3M, 
N4M, N17O, NK1, and N14G strain infection.
MATERIALS AND METHOD
Streptococcus agalactiae bacteria
Bacteria of S. agalactiae from N3M, N4M, 
N17O, N14G isolates were obtained from the Center 
for Research and Development of Freshwater 
Aquaculture, Bogor, West Java, Indonesia. Five 
strains of S. agalactiae bacterial virulence was 
recovered with Koch’s postulate test. Bacteria 
were cultured in brain heart infusion broth 
(BHIB) liquid media for 72 hours on 140 rpm 
shaker and injected on fish as much as 0.1 mL 
in the intraperitoneal body part. Bacteria were 
isolated from the fish suffered the clinical signs 
of S. agalactiae. Isolation result was purified and 
characterized with Kit API 20 Strep. 
Vaccine production
Vaccine production from S. agalactiae N3M 
and N4M strain were cultured in the liquid media 
for 72 hours (109 CFU/mL bacterial density), 
added with 38% neutral formalin buffer (NBF) 
as much as 3% of the liquid culture volume, and 
incubated for 24 hours. Bacteria were harvested 
using 7000 rpm centrifugation for 30 minutes 
and washed with phosphate buffered saline 
(PBS) twice, then added with PBS based on the 
initial volume. The vaccine produced was tested 
its viability level on brain heart infusion agar 
(BHIA) media.
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Tank preparation and experimental fish 
rearing 
As many as 48 pieces of aquarium tanks 
sized (60×30×50) cm3 with set aeration on each 
tank were prepared. Aquarium was washed 
and filled with water reaching 25 cm height, 
then disinfected along with the media using 30 
mg/L of chlorine (Ca(ClO)2) for 24 hours and 
neutralized with sodium thiosulfate (Na2S2O3) as 
much as 15 mg/L. As many as 10 fish on each 
aquarium was maintained and given commercial 
feed three times a day with satiation. Water media 
was replaced as much as 75% of the volume every 
three days. Water quality maintained during the 
rearing process was 25.8‒26.6°C of temperature, 
6.7‒7.1 of pH, 5.26‒6.23 of dissolved oxygen, 
and 0.0019‒0.0038 of TAN.  
Vaccination and challenge test 
 Fish was vaccinated with 0.1 mL dose of two 
vaccines of N3M (vaccine A) and N4M (vaccine 
B) strain for each fish on the intraperitoneal part. 
Challenge test was conducted after 14 days of 
vaccination using S. agalactiae N3M (bacteria a), 
N4M (bacteria b), N17O (bacteria c), NK1 (bacteria 
d), and N14G (bacteria e) strains with 0.1 mL dose 
of 107, 107, 106, 106, 106 CFU/fish respectively 
(Based on LD50).
Design
This study used factorial complete randomized 
design method containing two factors, which 
were S. agalactiae vaccine strain (N3M (vaccine 
A) and N4M (vaccine B)) and challenge test (S. 
agalactiae N3M (a), N4M (b), N17O (c), NK1 (d), 
and N14G (e) strain) types with three replications.
Parameter 
Parameters observed in this study were 
mortality rate, relative percent survival, 
antibody level (ELISA), blood characterization 
(erythrocyte total, leucocyte total, hematocrit, 
hemoglobin, phagocytic activity, and respiratory 
burst), lysozyme activity, and clinical signs. 
Blood characterization, antibody levels, and 
lysozyme activity parameter were observed before 
vaccination, two weeks after vaccination, and 
a week after the challenge test. Mortality range 
and relative percent  survival were observed two 
weeks after challenge.    
Relative percent survival 
Relative percent survival (RPS) was calculated 
to measure the vaccine protection level against 
S. agalactiae infection on the fry sample. The 
relative percent survival was calculated on the 
following formula. 
 
Antibody level
Antibody level was measured using an indirect 
method of enzyme-linked immunosorbent 
assay (ELISA), based on Sumiati et al. (2015). 
S. agalactiae antigen was obtained from the 
sonication result. Protein concentration on antigen 
was measured with Bradford spectrophotometry 
method and diluted with carbonate-bicarbonate 
buffer (pH 9.6) until reaching 10 µg/mL 
concentration. As much as 100 µL diluted 
antigen was put into the microtiter plate wells 
and incubated for 12 hours at 4°C. The microtiter 
plate was washed with PBS-T (PBS, pH 7.4 + 
0.05% Tween-20). Bovine serum albumin (BSA) 
3% in aquabidest w/v was added 100 µL on the 
well and incubated at 25°C for an hour, then 
washed with PBS-T. Tilapia serum samples were 
diluted with 1:50 PBS-T, added to the microtiter 
plate wells in accordance with 100 µL antigen. 
The microtiter plate was incubated at 25°C for an 
hour and washed with PBS-T. A hundred µL long 
Table 1. Experimental design 
Vaccine
Challenge test
N3M (a) N4M (b) N17O (c) NK1 (d) N14G (e)
K(-) K-a K-b K-c K-d K-e
K(+) K+a K+b K+c K+d K+e
N3M (A) Aa Ab Ac Ad Ae
N4M (B) Ba Bb Bc Bd Be
Note: Control without vaccination and challenge test (K-), with a challenge test (K+). Vaccination using N3M (A) 
and N4M (B) vaccine, challenged with N3M (a), N4M (b), N17O (c), NK1 (d), N14G (e) strain.
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chain immunoglobulin of anti-tilapia for a specific 
polyclonal antibody which had been diluted 1:200 
(v/v) with PBS-T was added on the microtiter 
plate well and incubated 25°C for an hour, then 
washed with PBS-T. Peroxidase-conjugated goat 
anti-rabbit diluted with PBS-T 1:15,000 was 
added 100 µL onto the microtiter plate wells and 
incubated at 25°C for 1 hour. The microtiter plate 
was washed with PBS-T and added with 100 µL 
of One Step Ultra-TMB-ELISA (TMB 5 mg + 10 
µL 38% H2O2 in 5 mL of acetate buffer pH 5), 
then incubated at 25°C for 15 minutes. ELISA 
reaction was stopped with the addition of 100 µL 
H2SO4 3 M into microtiter plate wells. Optical 
density on the microtiter plate was read using 
a Microplate Reader (Kayto RT-2100C) with 
450 nm wavelength. The cut off value (CV) was 
determined as the antibody formation standard. 
The optical density with a higher value than CV 
would represent antibody existence. CV value 
was determined with the following formula: 
Erythrocyte total
Blood which was taken from the fish sample 
was absorbed using red pulpy Sahli pipette until 
scale 0.5 and diluted using Hayem’s solution 
until reaching scale 101. Blood solution was 
homogenized by shaking the pipette forming 
number eight for 3-5 minutes. One drop of blood 
was thrown to eliminate the unmixed blood part 
and closed with cover glass. Total erythrocyte was 
calculated using :   
 
Hemoglobin 
Hemoglobin was measured based on Sahli 
method using haemometer. Hemoglobin tube was 
filled with 0.1 N HCl until reaching scale 10 on 
the red scale. Blood was taken using Sahli pipette 
until scale 20 and put into the hemoglobin tube, 
then steadied for 5 minutes. The solution was 
added with aquadest until the solution color was 
the same as the standard color. Hemoglobin level 
was read on the yellow scale (g/dL).
Hematocrit 
Hematocrit was measured to determine the 
blood cell percentage existed in the fish blood. 
Fish blood was taken in the microhematocrit tube 
until ¾ part of the tube, then the tube tip was 
closed using crytoceal. Tube filled with fish blood 
was centrifuged using 3000 rpm for 5 minutes. 
Hematocrit content was determined with the 
following formula:
 
Leucocyte total
Blood was absorbed using white pulpy Sahli 
pipette until scale 0.5 and added with Turk’s 
solution until scale 11, then homogenized for 3-5 
minutes by shaking the pipette to form a number 
eight. One to two solution drops from the pipette 
was thrown and another one was dropped on the 
haemocytometer. Leucocyte total was calculated 
with : 
  
Phagocytic activity (PA)
Staphylococcus aureus bacteria with 107 CFU/
mL was added on the blood in the sterile microtube 
with 1:1 ratio and incubated for 20 minutes at 
the room temperature. The blood sample was 
spread thinly on the object glass and dried at the 
room temperature. The blood sample was fixated 
using methanol 95% for 5 minutes. The blood 
sample was dried and colored with Giemsa 5% 
for 15 minutes, then cleaned with aquadest. The 
phagocytic activity on blood sample was observed 
using a microscope and counted 100 phagocytic 
cells (monocytes and neutrophils). Observation 
result was calculated with the following formula: 
Respiratory burst (RB)
Respiratory burst measurement was based 
on the nitroblue tetrazolium (NBT) reduction 
existence as the anion superoxide. The blood 
sample was put into the microtiter plate as much 
as 50 µL and incubated at 37°C for 1 hour. Blood 
inside the microtiter plate was thrown and cleaned 
with PBS pH 7.4 three times. 100 µL NBT (0.2% 
in PBS pH 7.4) was added in the microtiter plate 
and incubated at 37°C for 1 hour, then cleaned 
using PBS. Methanol absolute was added as 
much as 100 µL and kept steady for 10 minutes, 
then thrown and cleaned with methanol 30% 
three times. A sample in the microtiter plate was 
172 Sukenda et al. / Jurnal Akuakultur Indonesia 17 (2), 168–180 (2018)
added with 60 µL KOH 1 M and 70 µL dimethyl 
sulfoxide (DMSO). Respiratory burst value was 
determined from the optical density read using 
Microplate Reader (Kayto RT-2100C) on 630 nm 
wavelength.      
Lysozyme activity
A hundred µL blood serum was put in 
a microtiter plate and added with a liquid 
suspension of Micrococcus lysodeikticus (Sigma) 
bacteria as much as 100 µL (0.4 mg/mL in 0.1 M 
PBS pH 6.2) at 25°C. Absorbance was read using 
Microplate Reader (Kayto RT-2100C) with 450 
nm wavelength for 30 seconds and 30 minutes 
mixing. Lysozyme activity measurement unit 
was based on the decreased 0.0001 per minute of 
optical density (OD) on the following formula:
 
Clinical signs
Clinical signs on the fry were observed after 
the challenge test conducted by comparing the 
external organ of the fry infected with and without 
S. agalactiae. Clinical signs observed were 
exopthalmus, dropsy, whirling, opacity, purulent, 
and discoloration.
Data analysis
Measured parameter data result was tabulated 
in Microsoft Office Excel 2007 and analyzed using 
analysis of variance (ANOVA) on Minitab 16 
application with 95% confidence level (P<0.05), 
as well as continued Tukey test.
RESULTS AND DISCUSSION 
Results
Mortality and relative percent survival
The mortality rate of fry vaccinated by vaccine 
A and B were lower significantly (P<0.05; Table 
2), compared with the positive control, except 
vaccine B treatment with d challenge test. The 
best mortality range was observed at vaccine A on 
a challenge test with 6.67 ± 5.77%. The highest 
relative percent survival on every vaccine type 
treatment was at vaccine A on a challenge test 
(87.50 ± 10.82%) and B on b challenge test (76.47 
± 10.18%) that both were significantly different 
(P<0.05) with d challenge test.
Antibody level
Antibody level after vaccination increased 
significantly (P<0.05; Table 3) for two vaccine 
types compared with control treatment, however, 
showing no significant difference among vaccine 
Table 2. Mortality rate (MR) dan relative percent survival (RPS) of fry tilapia on two weeks after the challenge test 
Vaccine Challenge test MR (%) RPS (%)
K- 0.00 ± 0.00f -
K+
a 53.33 ± 5.77ab -
b 56.67 ± 5.77a -
c 56.67 ± 5.77a -
d 60.00 ± 10.00a -
e 56.67 ± 5.77a -
A
a 6.67 ± 5.77ef 87.50 ± 10.82a
b 20.00 ± 10.00cde 64.70 ± 17.64abc
c 26.67 ± 5.77cd 52.94 ± 10.18bc
d 33.33 ± 5.77c 44.44 ± 9.62bc
e 26.67 ± 5.77cd 52.94 ± 10.18bc
B
a 20.00 ± 10.00cde 62.5 ± 18.75abc
b 13.33 ± 5.77def 76.47 ± 10.18ab
c 30.00 ± 0.00cd 47.05 ± 0.00bc
d 36.67 ± 5.77bc 38.89 ± 9.62c
e 26.67 ± 5.77cd 52.94 ± 10.18bc
Note: Different superscript letter in the same column shows a significant difference (P<0.05).  Control without 
vaccination and challenge test (K-), with a challenge test (K+). Vaccination using N3M (A) and N4M (B) vaccine, 
challenged with N3M (a), N4M (b), N17O (c), NK1 (d), N14G (e) strain.
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treatments. Antibody level formed from vaccine 
treatment was higher than CV. OD value for 
vaccine A treatment was 0.767 ± 0.026 and 
vaccine B was 0.743 ± 0.026. Antibody level after 
challenge test was significantly different (P<0.05) 
on vaccine type treatments and their interactions, 
however, it showed no significant difference on 
the challenge test (P>0.05). Antibody level on 
vaccine A and B treatment increased significantly 
on the challenge test treatment (P<0.05; Table 
3) compared with negative and positive control, 
however, there was no significant difference 
(P>0.05) compared among vaccine treatments on 
all challenge tests. OD value on vaccine treatment 
with different challenge test was higher than the 
cut of value. The highest OD value was observed 
at vaccine A treatment on a challenge test with 
0.830±0.014 and vaccine B treatment on b 
challenge test with 0.887 ± 0.023.  
Blood characterization
Erythrocyte total after vaccination on vaccine 
B treatment was significantly different (P<0.05) 
compared with control treatment. Erythrocyte 
total after challenge test on vaccine A treatment 
with b, d challenge test and vaccine B treatment 
with a challenge test were significantly different 
(P<0.05) compared with the a, b, and d control 
challenge test. Leucocyte total on the vaccine 
A and B treatment were significantly higher 
(P<0.05) than control treatment after vaccination. 
Leucocyte total after challenge test on vaccine 
A treatment with all challenge tests and vaccine 
B with d challenge test exception differed 
significantly (P<0.05) compared with the control 
treatment on c challenge test. Hemoglobin level on 
vaccine A after a, c, e challenge test and vaccine 
B after a challenge test was significantly different 
(P<0.05) compared with control treatment on a 
challenge test. Hematocrit level after vaccination 
on all treatments had no significant difference 
(P>0.05). 
Table 3. Antibody level of fry tilapia with N3M and N4M antigen, before and after vaccination, as well as after the 
challenge test 
Treatment
N3M Antigen-antibody level
 (optical density)
N4M Antigen-antibody level 
(optical density)
Before vaccination
Initial 0.492 ± 0.058 Initial 0.462 ± 0.014
After vaccination
Control 0.587 ± 0.024b Control 0.544 ± 0.005b
A 0.767 ± 0.026a B 0.743 ± 0.026a
CV 0.635 CV 0.554
After challenge test
K- 0.477 ± 0.026d K- 0.549 ± 0.057cd
K+
a 0.487 ± 0.024d
K+
a 0.611 ± 0.029c
b 0.505 ± 0.028cd b 0.484 ± 0.029d
c 0.523 ± 0.010cd c 0.563 ± 0.031cd
d 0.520 ± 0.018cd d 0.500 ± 0.026cd
e 0.501 ± 0.041cd e 0.593 ± 0.019cd
A
a 0.830 ± 0.014ab
B
a 0.748 ± 0.014b
b 0.821 ± 0.015ab b 0.887 ± 0.023a
c 0.766 ± 0.009b c 0.744 ± 0.024b
d 0.790 ± 0.013ab d 0.756 ± 0.028b
e 0.767 ± 0.030b e 0.762 ± 0.028b
CV 0.530 CV 0.664
Note: Different superscript letter in the same column shows a significant difference  (P<0.05). Control without 
vaccination and challenge test (K-), with a challenge test (K+). Vaccination using N3M (A) and N4M (B) vaccine, 
challenged with N3M (a), N4M (b), N17O (c), NK1 (d), N14G (e) strain. CV is cut of value as an antibody formed 
standard.
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Hematocrit level on vaccine A after a, b, 
and e challenge test was significantly different 
(P<0.05) compared with control treatment after 
c and d challenge test. Vaccine B treatment 
on all challenge tests showed no significant 
different (P>0.05) against two control treatments. 
Phagocytic activity after vaccination on vaccine 
A and B were significantly different (P<0.05) 
from control treatment. Phagocytic activity on 
vaccine A and B after all challenge test treatments 
were significantly different (P<0.05) with 
positive control. Respiratory burst (RB) level 
after vaccination had no significant difference 
in all treatments (P>0.05). RB level on vaccine 
A and B after all challenge test treatments had a 
significant difference (P<0.05) against positive 
control treatment after b, c, and e challenge test. 
Lysozyme activity after vaccination on vaccine 
A and B were significantly different (P<0.05) 
from control treatment. Lysozyme activity on 
vaccine A after e challenge test and vaccine B 
after a challenge test had no significant difference 
compared with control treatment after b, c, and d 
challenge test.      
Clinical signs
Based on the observation result, the clinical 
signs occurred on fry tilapia were blackish body 
color, purulent, dropsy, opacity, whirling, and 
exophthalmia. 
Discussion
Vaccination used formalin-killed cells vaccine 
of bacteria S. agalactiae strains N3M (A) and N4M 
(B) given was able to lower the mortality rate of 
tilapia fry from Streptococcosis. The mortality 
rate of fish fry vaccinated was significantly 
lower (P<0.05) compared with the positive 
control, except vaccine B vaccine on d challenge 
test treatment. The lowest mortality rates from 
vaccine treatments were vaccine A on a challenge 
test (6.67±5.77%) and vaccine  B on b challenge 
test (13.33 ± 5.77%). The mortality rate of tilapia 
fry infected with the same bacteria as the vaccine 
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1. Clinical signs of tilapia fry infected S. agalactiae. Negative control (a), Negative control fry from the top 
(b), blackish body change (c), purulent (d), dropsy (e), opacity (f), whirling (g), exophthalmia (h).
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was lower than the different bacteria infection, 
which showed that the vaccine worked specifically 
against homologous bacteria. Giordano et al. 
(2010) reported that tilapia fish mortality rate 
which injected with inactive bacteria of S. 
agalactiae was 10.74%, based on the challenge 
test with homologous bacteria. This study reports 
that vaccine challenged with different bacteria 
had 20‒36.67% mortality rate. Shoemaker et al. 
(2010) reported that fish mortality rate observed 
from the S. iniae vaccination using four strains 
were ranged from 0‒7.5% after the challenge test. 
The mortality rate of tilapia vaccinated with one 
type of vaccine and tested using 10 combined 
strains of S. agalactiae was ranged 40‒80% (Chen 
et al., 2012). All treatments on d challenge test 
(NK1) had the highest mortality rate from control 
treatment with 60%, vaccine A treatment with 
33.33%, and vaccine B with 36.67%. According 
to Hardi et al. (2011), the bacteria strain NK1 
used to challenge test had virulence which was 
higher than the other. Vaccine A treatment had an 
averagely low mortality rate after challenged with 
different bacteria. 
The increased protection level of tilapia 
against streptococcosis indicated the relative 
percent survival. The relative percent  survival 
of both vaccines with different challenge tests 
showed different results. Tilapia relative percent 
survival on vaccine A after a, b, c, d and e 
challenge test were 62.50%, 76.47%, 47.05%, 
38.89%, and 52.94%, respectively. Vaccine A was 
capable of protecting more than 50% infection of 
S. agalactiae strains a, b, c, and e, while vaccine 
B was capable of protecting from the bacterial 
infection from a, b, and e strains. The vaccine 
produced that was homologous with bacteria 
gives higher protection than the different bacteria 
after the challenge test. Homologous antigen 
comes from other individuals in one species. 
Meanwhile the heterologous antigen comes 
from other individuals in other species. The 
difference source of antigen will usually produce 
different immune response compared to other 
(Munang’andu et al., 2016).
Evans et al. (2004) showed tilapia vaccinated 
and challenged with the heterologous bacteria 
generated 25% of relative percent survival, 
whereas with the bacterial homologous was 
70%. Vaccine A and B for homologous bacterial 
protection also provided heterologous infected 
bacterial protection, called cross-protection. Chen 
et al. (2012) showed three among ten vaccine 
types were capable of protecting from different 
strains and genotypes of S. agalactaie with relative 
percent survival ranged 53.57‒100%. Vaccine 
protection from S. iniae infection in tilapia with 
four different strains showed different relative 
percent survival, ranging 79‒100% (Shoemaker 
et al., 2010). Based on the result obtained in this 
study, vaccine A gave a lot more protection from 
different S. agalactiae strains. 
Parameters of the mortality and relative percent 
survival on vaccination treatment were influenced 
by the specific immune system followed with a 
non-immune system. Vaccination performed 
stimulated the formation of the specific immune 
system shown with increased antibody level in 
fish. Increased antibody level was supported by 
the activity of T cell (T helper cells, cytotoxic T 
cells, and memory T cells) and B cells (B cells and 
plasma B cell memory). The interaction between 
antigen and lymphocytes (B cells and T cells) 
caused an increased level of antibodies through 
vaccination. The vaccine contained antigens 
which induced the proliferation of B cells into 
memory B cells and plasma B cells. The role of 
memory B cells stored information characteristics 
of the antigen into the body, while the plasma B 
cells played a role in the production of specific 
antibodies against these antigens. Incoming 
antigen was phagocytized by macrophages, the 
process of antigen phagocytosis would transfer 
helper T cells via major histocompatibility 
complex (MHC) class II. Macrophage would 
activate helper T cells through cytokine 
molecules. Helper T cells produced cytokines that 
stimulated B cells, memory T cells, and cytotoxic 
T cells. The same antigen that penetrated the body 
for the second time would stimulate the role of 
memory T cells and memory B cells to conduct 
proliferation into the plasma cells as well as 
producing antibodies (Mashoof et al., 2016).
Antibody levels after vaccination on both 
vaccine treatments happened to conduct an 
increased level of specific antibodies against S. 
agalactiae strain A and B. This was shown on the 
value of vaccine A (0.767 ± 0.026) and B (0.743 ± 
0.026) optical density (OD) which were higher than 
any vaccine the cut of value (CV). Both vaccine 
treatments showed a significant increase (P<0.05) 
compared with the control treatment. Martins et 
al. (2011) also reported increased antibody level 
in tilapia serum compared with control treatment, 
after vaccinated with vaccines S. iniae. The 
antibody level after challenge test on vaccine A 
and B treatment was significantly higher (P<0.05) 
than positive and negative control treatment as 
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well as higher than CV. OD value on vaccine A 
after a,b,d challenge test treatment and vaccine B 
after all challenged tests were increased compared 
with OD value after vaccination. Increased 
OD value after challenge test also occurred 
on Sukenda et al. (2015), who reported that 
measurable antibodies were correlated with the 
relative percent survival. Increased OD treatment 
on vaccine A after all challenge tests were not 
significantly different (P>0.05) with vaccine B 
after a, c, d and e challenge test. Measurement 
of antibody level after challenge test using the 
same vaccine antigens, making the measured OD 
value was obtained from the antibodies formed 
from the same antigen and vaccines. This caused 
the OD value after challenge test was not much 
different to the value OD after vaccination. This 
result was on the contrary from Shomaker et al. 
(2010), who used the same antigen as a vaccine to 
testify the antibody level of fish vaccinated with 
S. iniae vaccine strain ARS-98-60 which was 
challenged with four different strains showed an 
increased antibody level. This was suspected to 
happen as of the protein profile of the five strains 
of S. agalactiae bacteria were used. Shomaker et 
al. (2010) stated that bacterial strains used had 
protein profile similarities inducing the antibody 
formation that allowed cross-protection. Based 
on antibody level measurement in this study, 
vaccine A had OD value that was higher after the 
challenge test treatments. 
The nonspecific immune system also had a 
role in mortality and relative percent survival 
which could be shown from hereditary immune 
system and hematology parameter (Sukenda et al., 
2017). Leucocyte total is one of the hematology 
parameters on the nonspecific immune system. 
Leucocyte total measured on vaccine A and 
B (2.23‒2.47×104 cell mm˗3) treatment after 
vaccination were significantly higher (P<0.05) 
than the control treatment, nevertheless 
showing no significant difference (P>0.05) on 
the vaccination treatments. Suanyuk and Itsaro 
(2011) also reported that the leucocyte total which 
had no significant difference between vaccination 
treatments. Leucocyte total on vaccine A and B 
treatment after all challenge tests (6.33‒10.47×104 
cell/mm3) were significantly higher (P<0.05) than 
the negative control. The vaccine was suggested 
as an antigen penetrating the fish body which was 
responded by producing leucocyte and forming an 
antibody, though it was less effective during the 
initial infection, or in this case was vaccination 
period (Sukenda et al., 2014). Increased leucocyte 
total after the challenge test showed that the fish 
body still defended against the infection. The 
highest leucocyte total was observed at vaccine A 
on c challenge test and vaccine B on b challenge 
test treatment. According to Hardi et al. (2013), 
vaccination was not yet completely capable of 
helping eliminate the pathogen existed in the 
body, which was marked as high leucocyte total 
after the challenge test.        
Leucocyte total is related to the phagocytic 
activity. Phagocytic activity on vaccine treatment 
A and B (32.33% and 34%) was significantly 
higher (P<0.05) than the control treatment after 
vaccination. Sukenda et al. (2018) showed that 
tilapia fish which were given FKC S. agalactiae 
vaccine differed significantly against the 
phagocytic activity. Improvement of phagocytic 
activity was in line with the significant increased 
of total leucocytes compared with control 
treatment. Phagocytic activity experienced an 
increased immune system, showing bacterial 
infection resistance after the challenge test. This 
was also supported by the leucocyte total and 
antibody level which were quite high after the 
challenge test. Formed antibodies after vaccination 
would accelerate the antigen elimination under 
opsonization process. Opsonized antigen will 
be more recognizable for macrophages as well 
as more effective to be destructed (Hardi et al., 
2013).  
The activity of phagocyte in destroying 
pathogen was indicated with the respiratory burst 
parameter. According to Uribe et al. (2011), the 
respiratory burst was produced by neutrophils 
and macrophages in the phagocytosis process to 
attack pathogens by producing reactive oxygen 
species (ROS). Phagocyte cells that successfully 
ingested pathogens would expose ROS as well 
as enzymes for pathogen digestion (Holmstrom 
& Finkel, 2014). The number of phagocyte cells 
exposed ROS was measured by NBT reduction 
method to become formazan in the form of 
optical density (OD). In this study, the value of 
the respiratory burst after vaccination vaccine 
treatment A and B did not differ significantly 
(P>0.05) with the control. Aly et al. (2015) also 
reported similar results with FKC vaccination on 
tilapia with Aeromonas hydrophila on respiratory 
burst parameter after vaccination. The value of 
the respiratory burst was significantly higher 
(P<0.05) on the vaccine treatment A and B after 
all challenge test treatments test challenge than 
control treatment after on b, c and e challenge test 
treatments. Pridgeon and Klesius (2013) showed 
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an increased production of ROS by macrophages 
of fish vaccinated against different bacteria after 
two and five minutes incubation compared with 
controls measured using the chemiluminescence 
assay method. The value of respiratory burst 
increased along with the phagocytic activity on 
the same treatment. 
Nonspecific immune response associated with 
the lysozyme activity is leucocytes. Lysozyme is 
an important component in the immune system 
that separates a peptidoglycan layer cell wall 
of Gram-positive bacteria for preventing from 
infection. The measurement of lysozyme was 
commonly used as an indicator for fish vaccination 
evaluation (Yi et al., 2014). This study discovered 
increased lysozyme activity after vaccinations 
on treatment A and B, which were significantly 
different (P < 0.05) with control treatment. 
Pasaribu et al. (2018) reported an increased 
lysozyme activity in the tilapia broodstock after 
vaccination was followed by its descendants. The 
lysozyme activity on vaccine A and B treatment 
was higher than the positive and negative control 
treatment. The increased activity of lysozyme 
would enhance the antibacterial ability in tilapia 
(Huang et al., 2013).
Nonspecific immune response parameter that 
affected the fish health status is the erythrocyte 
total. Measured erythrocyte total after vaccination 
showed a significantly lower decline on vaccine B 
treatment (P<0.05) than control treatment, while 
vaccine A treatment was not significant difference 
compared with the control treatment (P>0.05). 
Martins et al. (2011) reported that the erythrocyte 
total of tilapia fish after vaccinated using S. iniae 
vaccine had declined result with no significant 
difference against the control treatment. Total 
erythrocyte decline was suspected because the 
vaccine given was suggested as an antigen, 
making the fish become more stressful along 
with the declined erythrocyte production and 
increased leucocyte production. Every treatment 
showed higher erythrocyte total compared with 
the control treatment. Different bacteria used for 
challenge test did not influence the erythrocyte 
total. According to Evans et al. (2005), vaccination 
was able to minimalize fish stress infected by the 
bacteria, making the energy needs to protect from 
S. agalactiae was less than the vaccinated fish.         
Hemoglobin parameter was related with the 
erythrocyte total which functioned as oxygen 
binder that was able to bring in all body parts. 
Hemoglobin level on vaccine B treatment 
had no significant difference (P>0.05) with 
control treatment after vaccination. Martins et 
al. (2011) reported that the hemoglobin level 
was not significantly differencing with the 
control treatment, which had a correlation with 
erythrocyte total and hematocrit. Hemoglobin 
level on vaccine A treatment after a,c,e challenge 
test and vaccine B treatment after e challenge 
test were significantly different (P<0.05) with 
the control treatment after a challenge test. 
Normal hemoglobin level of fish was 5.8±1.04% 
(Lourenco et al., 2012).  
Fish health status parameter associated with 
erythrocytes is hematocrit. Hematocrit shows the 
percentage of the total volume of blood cells in fish. 
Hematocrit on vaccine A and B after vaccination 
did not differ significantly (P<0.05) with the 
control. Suanyuk and Itsaro (2011) reported 
that hematocrit level on tilapia vaccinated with 
S. iniae vaccine was not significantly different 
with the control treatment. Vaccine treatment had 
higher hematocrit level compared with positive 
control. Martin et al. (2011) also reported that the 
vaccinated fish showed higher hematocrit level 
during 18 days after challenge test compared with 
the control treatment.
Clinical signs due to the infection of S. 
agalactiae strains N3M, N4M, N17O, NK1, and N14G 
were black skin color change, opacity, dropsy, 
purulent, whirling and exophthalmia (Figure 1). 
Clinical signs generally appeared on the fifth day 
after the challenge test. Based on the research of 
Hardi et al. (2011), clinical signs appeared after 
infection were shrunk pupil, opacity, purulent, 
exophthalmia, followed with bleeding, blackened 
discoloration, stomach ulcer, abscess, whirling 
and gasping. These signs appeared after 24 hours 
after the challenge test.
CONCLUSION
Based on the result obtained, it concluded 
that tilapia fry after vaccinated with S. agalactiae 
N3M dan N4M strain showed the increased 
level of antibodies, leucocyte total, phagocytic 
activity, respiratory burst, and lysozyme activity. 
Vaccine S. agalactiae N3M strain was capable 
of protecting the fry from N3M, N4M, N17O, and 
N14G strain, while N4M strain vaccine was only 
capable of protecting the fry from N3M, N4M, and 
N14G strain.  
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